| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
58,160,000 |
| Market
Cap: |
5.82(B) |
| Last
Volume: |
5,449,206 |
Avg
Vol: |
5,434,465 |
| 52
Week Range: |
$99.99 - $99.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chalmers Derek T |
Former VP, Research and Dir. |
– – – |
2004-06-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,833) |
370,667 |
|
- |
|
| Beeley Nigel R A |
Former VP, Chief Chem. Officer |
– – – |
2004-06-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
70,907 |
|
- |
|
| Maffuid Paul W |
VP, Pharmaceutical Development |
• – – |
2004-03-31 |
4 |
A |
$5.10 |
$989 |
D/D |
194 |
16,388 |
|
- |
|
| Spector Steven W |
VP, General Counsel & Sec |
• – – |
2004-03-31 |
4 |
A |
$5.10 |
$2,703 |
D/D |
530 |
43,200 |
|
- |
|
| Williams Joyce H |
VP, Drug Development |
• – – |
2004-03-31 |
4 |
A |
$5.10 |
$3,188 |
D/D |
625 |
81,698 |
|
- |
|
| Hoffman Robert |
VP, Finance |
• – – |
2004-03-31 |
4 |
A |
$5.45 |
$589 |
D/D |
108 |
51,767 |
|
- |
|
| Beeley Nigel R A |
VP, Chief Chemical Officer |
• – – |
2004-03-31 |
4 |
A |
$5.10 |
$3,188 |
D/D |
625 |
85,907 |
|
- |
|
| Lief Jack |
President and CEO |
• • – |
2004-03-31 |
4 |
A |
$5.10 |
$3,188 |
D/D |
625 |
569,883 |
|
- |
|
| Belcher Donald D |
Director |
– • – |
2004-03-23 |
4 |
B |
$6.28 |
$31,496 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Scotti Louis J |
VP, Marketing and Business Dev |
• – – |
2004-03-22 |
4 |
S |
$6.39 |
$95,976 |
D/D |
(15,000) |
46,757 |
|
- |
|
| Hoffman Robert |
Vice President, Finance |
• – – |
2004-01-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
200 |
51,659 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2004-01-21 |
4 |
S |
$6.00 |
$297,000 |
I/I |
(49,500) |
1,556,351 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2004-01-20 |
4 |
S |
$6.00 |
$570,000 |
I/I |
(95,000) |
1,580,351 |
|
- |
|
| Lief Jack |
President and CEO |
• • – |
2004-01-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,625 |
569,258 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2004-01-14 |
4 |
S |
$6.05 |
$574,750 |
I/I |
(95,000) |
1,626,351 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2004-01-09 |
4 |
S |
$6.30 |
$151,200 |
I/I |
(24,000) |
1,672,351 |
|
- |
|
| Maffuid Paul W |
VP, Pharmaceutical Development |
• – – |
2003-12-31 |
4 |
A |
$5.10 |
$449 |
D/D |
88 |
16,194 |
|
- |
|
| Spector Steven W |
VP, General Cousel & Secretary |
• – – |
2003-12-31 |
4 |
A |
$5.10 |
$1,499 |
D/D |
294 |
42,670 |
|
- |
|
| Williams Joyce H |
VP, Drug Development |
• – – |
2003-12-31 |
4 |
A |
$5.10 |
$3,188 |
D/D |
625 |
81,073 |
|
- |
|
| Lief Jack |
President and CEO |
• • – |
2003-12-31 |
4 |
A |
$5.10 |
$3,188 |
D/D |
625 |
581,883 |
|
- |
|
| Beeley Nigel R A |
VP, Chief Chemical Officer |
• – – |
2003-12-31 |
4 |
A |
$5.10 |
$3,188 |
D/D |
625 |
85,282 |
|
- |
|
| Mooney Joseph F |
Former Chief Financial Officer |
– – – |
2003-12-31 |
4 |
A |
$5.10 |
$1,591 |
D/D |
312 |
27,473 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2003-12-31 |
4 |
S |
$6.20 |
$7,359,400 |
I/I |
(1,187,000) |
1,684,351 |
|
- |
|
| Lampert Mark N |
Director |
– • • |
2003-10-17 |
4 |
S |
$7.69 |
$22,385,590 |
I/I |
(2,911,000) |
4,520,212 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2003-10-17 |
4 |
S |
$7.69 |
$22,385,590 |
I/I |
(2,911,000) |
2,259,351 |
|
- |
|
415 Records found
|
|
Page 16 of 17 |
|
|
